LENZ Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

LENZ Therapeutics (Nasdaq: LENZ) announced management will present at three investor conferences in early December 2025: Piper Sandler on Dec 2, 2025 in New York (fireside chat 3:30pm ET), Evercore on Dec 3, 2025 in Coral Gables (fireside chat 1:20pm ET), and Citi Global Healthcare on Dec 4, 2025 in Miami (fireside chat 10:30am ET).

Each event includes live audio webcasts and 1x1 investor meetings. Webcasts will be available on the company website in the Investors & Media section, with replays accessible for 12 months after each event. The company commercializes VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults.

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:

Piper Sandler 37^th Annual Healthcare Conference
Date: December 2, 2025
Location: New York City, NY
Format: Fireside chat at 3:30pm ET (live audio webcast) and 1x1 investor meetings

8^th Annual Evercore Healthcare Conference
Date: December 3, 2025
Location: Coral Gables, FL
Format: Fireside chat at 1:20pm ET (live audio webcast) and 1x1 investor meetings

Citi’s 2025 Global Healthcare Conference
Date: December 4, 2025
Location: Miami, FL
Format: Fireside chat at 10:30am ET (live audio webcast) and 1x1 investor meetings

Live audio webcasts will also be available on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcasts will be available on the Company’s website for 12 months following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ^TM (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

FAQ

When will LENZ (NASDAQ: LENZ) present at the Piper Sandler 37th Annual Healthcare Conference?

LENZ management will present on Dec 2, 2025 in New York with a fireside chat at 3:30pm ET and a live audio webcast.

How can investors watch LENZ's fireside chats on Dec 2–4, 2025?

Live audio webcasts for all three events will be available on the LENZ website in the Investors & Media section, with replays for 12 months.

What time is LENZ scheduled to present at the Evercore Healthcare Conference (Dec 3, 2025)?

LENZ has a fireside chat at the Evercore conference on Dec 3, 2025 at 1:20pm ET in Coral Gables.

Will LENZ hold investor meetings at the Citi 2025 Global Healthcare Conference on Dec 4, 2025?

Yes, LENZ management will conduct 1x1 investor meetings at the Citi conference in Miami and host a fireside chat at 10:30am ET.

Where can I find replay recordings of LENZ investor presentations from Dec 2025?

Replays will be posted on the LENZ Investors & Media webpage and remain available for 12 months after each event.

What product does LENZ Therapeutics commercialize as noted in the investor conference announcements?

LENZ commercializes VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults.